YMAB Quote, Financials, Valuation and Earnings

Amicus Therapeutics has a net margin of -24.86% compared to Y-mAbs Therapeutics's net margin of -17.31%. Y-mAbs Therapeutics's return on equity of -30.14% beat Amicus Therapeutics's return on equity of -17.7%.

Y-mAbs Therapeutics has a consensus price target of $14.70, signalling upside risk potential of 237.93%. On the other hand Amicus Therapeutics has an analysts' consensus of $15.82 which suggests that it could grow by 160.6%. Given that Y-mAbs Therapeutics has higher upside potential than Amicus Therapeutics, analysts believe Y-mAbs Therapeutics is more attractive than Amicus Therapeutics.

Y-mAbs Therapeutics has a beta of 0.506, which suggesting that the stock is 49.403% less volatile than S&P 500. In comparison Amicus Therapeutics has a beta of 0.508, suggesting its less volatile than the S&P 500 by 49.181%.

Y-mAbs Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Y-mAbs Therapeutics pays -- of its earnings as a dividend. Amicus Therapeutics pays out -- of its earnings as a dividend.

Y-mAbs Therapeutics quarterly revenues are $20.9M, which are smaller than Amicus Therapeutics quarterly revenues of $125.2M. Y-mAbs Therapeutics's net income of -$5.2M is higher than Amicus Therapeutics's net income of -$21.7M. Notably, Y-mAbs Therapeutics's price-to-earnings ratio is -- while Amicus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Y-mAbs Therapeutics is 2.19x versus 3.42x for Amicus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -24.86% compared to Y-mAbs Therapeutics's net margin of -49.65%. Y-mAbs Therapeutics's return on equity of -30.14% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Y-mAbs Therapeutics has a consensus price target of $14.70, signalling upside risk potential of 237.93%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.62%. Given that Y-mAbs Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Y-mAbs Therapeutics is more attractive than NovaBay Pharmaceuticals.

Y-mAbs Therapeutics has a beta of 0.506, which suggesting that the stock is 49.403% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Y-mAbs Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Y-mAbs Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Y-mAbs Therapeutics quarterly revenues are $20.9M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Y-mAbs Therapeutics's net income of -$5.2M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Y-mAbs Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Y-mAbs Therapeutics is 2.19x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -24.86% compared to Y-mAbs Therapeutics's net margin of --. Y-mAbs Therapeutics's return on equity of -30.14% beat Oragenics's return on equity of --.

Y-mAbs Therapeutics has a consensus price target of $14.70, signalling upside risk potential of 237.93%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 2012.89%. Given that Oragenics has higher upside potential than Y-mAbs Therapeutics, analysts believe Oragenics is more attractive than Y-mAbs Therapeutics.

Y-mAbs Therapeutics has a beta of 0.506, which suggesting that the stock is 49.403% less volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

Y-mAbs Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Y-mAbs Therapeutics pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Y-mAbs Therapeutics quarterly revenues are $20.9M, which are larger than Oragenics quarterly revenues of --. Y-mAbs Therapeutics's net income of -$5.2M is lower than Oragenics's net income of -$2.2M. Notably, Y-mAbs Therapeutics's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Y-mAbs Therapeutics is 2.19x versus 0.45x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -24.86% compared to Y-mAbs Therapeutics's net margin of --. Y-mAbs Therapeutics's return on equity of -30.14% beat Theriva Biologics's return on equity of --.

Y-mAbs Therapeutics has a consensus price target of $14.70, signalling upside risk potential of 237.93%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1402.15%. Given that Theriva Biologics has higher upside potential than Y-mAbs Therapeutics, analysts believe Theriva Biologics is more attractive than Y-mAbs Therapeutics.

Y-mAbs Therapeutics has a beta of 0.506, which suggesting that the stock is 49.403% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

Y-mAbs Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Y-mAbs Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Y-mAbs Therapeutics quarterly revenues are $20.9M, which are larger than Theriva Biologics quarterly revenues of --. Y-mAbs Therapeutics's net income of -$5.2M is lower than Theriva Biologics's net income of -$4.3M. Notably, Y-mAbs Therapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Y-mAbs Therapeutics is 2.19x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.